Intravenous Immunoglobulin Market 2022 - Market Size & Forecast, Industry Trends, Manufacturers Analysis, & Opportunities 2030

The global intravenous immunoglobulin market is estimated to witness growth at a compounded annual growth rate (CAGR) of 7.0% during the forecast period of 2022-2030.

Intravenous immunoglobulin (IVIG) is a blood product or therapy which involves the usage of a mixture of polyvalent antibodies (immunoglobulins) which are extracted from the plasma of blood donors to treat health conditions, including; immune thrombocytopenic purpura, hypogammaglobulinemia, Kawasaki disease, Guillain-Barré syndrome, primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, certain cases of HIV/AIDS and measles, and various other infections. Depending on its formulation, it can be administered into the muscle, a vein, or under the skin. Individuals or patients who cannot produce adequate antibodies get benefit from IVIg to maintain the appropriate level of antibodies in their bodies.

Growth Drivers:

Factors primarily attributed to the growth of this market include the burgeoning adoption and demand of novel intravenous immunoglobulins for the treatment of various diseases; the ever-growing number of hemophilic patients; the enhancing technologies pertaining to the immunoglobulin production coupled with improved purification techniques; the escalating demand for more reliable and adequate treatment measures, and the soaring investments in the healthcare sector across the globe.

Immunodeficiency & autoimmune diseases including chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others minimize the production of antibodies in the patients. The rising incidences of these diseases across the globe lead to increased adoption of immunoglobulin therapies for proper treatment. Alongside, the rapidly surging old-age population worldwide that is vulnerable to most chronic illnesses due to low immunity is further fueling the adoption of intravenous immunoglobulin (IVIG).

Moreover, the number of advancements and new product launches in the intravenous immunoglobulin market is swiftly escalating. This also includes the launch of various alternative therapies that generate more awareness regarding immunoglobulin. Also, the soaring approvals of various IVIG drugs from the European Medicine Agency (EMA), Food and Drug Administration (FDA), and other government agencies are opening up new growth and revenue opportunities for the market players present in the global intravenous immunoglobulin market.

Furthermore, other factors such as the growing research and development activities and investments; the increasing government expenditure on the healthcare industry; the increasing awareness pertaining to IVIG; the fast-paced innovation and development of blood plasma-derived products, and the proliferating IVIG usage in off-label indications are expected to further augment the growth of the global intravenous immunoglobulin market during the forecast period.

However, factors such as the stringent regulatory approval processes and regulations toward the vigorous use of intravenous immunoglobulin products, the high cost of therapy, and the risk of side effects associated with intravenous immunoglobulin products are expected to hinder the growth of the global intravenous immunoglobulin market during the forecast period.

Intravenous Immunoglobulin Market Segmentation:

By Type:

·         IgG

·         IgA

·         IgM

·         IgE

·         IgD

By Application:

·         Hypogammaglobulinemia

·         Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

·         Immunodeficiency Disease

·         Myasthenia Gravis

·         Multifocal Motor Neuropathy

·         Idiopathic Thrombocytopenic Purpura (ITP)

·         Inflammatory Myopathies

·         Specific Antibody Deficiency

·         Guillain–Barré Syndrome

·         Others

By Region:

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Based on application, the hypogammaglobulinemia segment acquired the largest share in the global intravenous immunoglobulin market in 2021. The segment is expected to further retain its lead in the market over the forecast period of 2022-2030. This can be attributed to the high number of cases of hypogammaglobulinemia worldwide. However, the immunodeficiency disease segment is anticipated to attain the highest growth rate during the forecast period owing to the wide availability of IVIG therapies and rising advancements in intravenous immunoglobulin products to treat the highly prevalent primary immunodeficiency diseases.

Regional Outlook:

The North American region held the largest share of the global intravenous immunoglobulin market in 2021, followed by Asia-Pacific. The region’s dominance is estimated to continue throughout the forecast period of 2022-2030. Factors predominantly ascribed to the large share of this region include the high number of patients requiring immunoglobulin treatment; the rising concerns pertaining to target diseases such as primary immunodeficiency diseases; the surging product approvals; the presence of the largest plasma production facilities, and a robust healthcare infrastructure; the proliferating adoption of IVIG healthcare system; the escalating research and development activities; the increasing payments to plasma donors to encourage plasma donation and boost yields, and the presence of leading market players in the region. The U.S. and Canada are the major contributors to the growth of the market in the region.

The Asia Pacific region accounted for the second-largest share of the global intravenous immunoglobulin market in 2021. The region is projected to achieve the fastest growth in the market during the forecast period, followed by Latin America, and the Middle East, and Africa. Factors such as: the burgeoning incidence of target diseases, the rapidly expanding healthcare and medical tourism industry, the escalating government support, the high presence of key intravenous immunoglobulin producers coupled with a robust distribution network, the rapidly soaring health care spending; the ever-growing patient and old-age population base, and the rising investments in the healthcare industry in the region are significantly contributing to the high growth of the intravenous immunoglobulin market in the Asia Pacific. Countries such as India, China, Japan, and South Africa are the leading contributors to the growth of the market in the region.

Key Companies in Intravenous Immunoglobulin Market:

·         Kedrion Biopharma Inc.

·         LFB group

·         Biotest AG

·         China Biologics Products Inc.

·         Bayer Healthcare

·         Baxter international Inc.

·         CSL Ltd.

·         Grifols S.A

·         Octapharma AG

·         Takeda Pharmaceutical Company Limited

·         Bio Products Laboratory Limited

·         Other Players